Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;36(5):646-650.
doi: 10.1111/pde.13926. Epub 2019 Jul 29.

Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature

Aslı Bilgic-Temel  1 , Züleyha Özgen  2 , Mehmet Harman  3 , Yelda Kapıcıoğlu  4 , Soner Uzun  5
Affiliations
Review

Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature

Aslı Bilgic-Temel et al. Pediatr Dermatol. 2019 Sep.

Abstract

Background/objectives: There is inadequate knowledge regarding rituximab (RTX) administration in autoimmune bullous diseases (AIBDs), disease prevalence, clinical characteristics, and treatment outcomes within pediatric populations due to the rarity of AIBDs affecting the pediatric age group. The aim of this retrospective analysis was to evaluate the effectiveness, safety of RTX, and treatment outcomes in Turkish pediatric patients with pemphigus vulgaris (PV) and to review the literature.

Methods: Five patients under 18 years of age and diagnosed with PV received RTX treatment and were identified in four dermatology departments of Turkey.

Results: The mean age of the patients at the time of RTX therapy initiation was 15 years (range: 11-17 years), and the total duration of follow-up after RTX therapy was 42.6 months (range: 19-60 months). All patients showed a clinical response. At the last visit, complete remission off therapy was achieved in three patients. The remaining two patients achieved partial remission off therapy. No adverse events were observed.

Conclusions: This retrospective case series of five pediatric patients showed that RTX treatment can be effective and safe for the treatment of recalcitrant PV in pediatric patients. With increasing evidence, RTX is a good treatment choice in adults and pediatric patients with pemphigus.

Keywords: childhood pemphigus; juvenile pemphigus; pediatric pemphigus; rituximab; therapy.

PubMed Disclaimer

References

REFERENCES

    1. V'lckova-Laskoska MT, Laskoski DS, Kamberova S, Caca-Biljanovska N, Volckova N. Epidemiology of pemphigus in Macedonia: a 15-year retrospective study (1990-2004). Int J Dermatol. 2007; 46: 253-258.
    1. Yayli S, Harman M, Baskan EB, et al. Epidemiology of pemphigus in Turkey: one-year prospective study of 220 cases. Acta Dermatovenerol Croat. 2017; 25( 3):181-188.
    1. Mabrouk D, Ahmed AR. Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris. Pediatr Dermatol. 2011;28:485-493.
    1. Fuertes I, Guilabert A, Mascaró JM Jr, Iranzo P. Rituximab in childhood pemphigus vulgaris: a longterm follow-up case and review of the literature. Dermatology. 2010;221:13-16.
    1. Baratta A, Camarillo D, Papa C, et al. Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF). Pediatr Dermatol. 2013;30:240-244.

LinkOut - more resources